

Supplementary Table 2. Cox regression analysis of risk factors for HCC progression in the overall patients (Vp1-4) (n = 85)

Variable	Univariate analyses			Multivariate analyses		
	HR	95% CI	<i>p</i> -value	aHR	95% CI	<i>p</i> -value
RT	0.69	0.40-1.17	0.17	0.63	0.37-1.09	0.10
Age (years)	0.98	0.95-1.00	0.07	-	-	-
Male	0.47	0.26-0.87	0.02	0.56	0.27-1.14	0.11
Presence of cirrhosis	0.74	0.44-1.25	0.26	-	-	-
HBsAg positivity	1.24	0.72-2.15	0.43	-	-	-
Anti-HCV positivity	0.92	0.37-2.32	0.87	-	-	-
Alcohol use disorder	0.91	0.49-1.69	0.78	-	-	-
ALT (U/L)	1.00	1.00-1.01	0.18	-	-	-
AST (U/L)	1.00	1.00-1.01	0.001	1.00	1.00-1.00	0.12
Bilirubin (mg/dL)	1.54	1.05-2.28	0.03	1.38	0.87-2.18	0.17
Albumin (g/dL)	0.80	0.57-1.12	0.19	-	-	-
PT (INR)	7.35	0.45-120.66	0.16	-	-	-
log _e AFP (ng/mL)	1.04	0.97-1.11	0.24	-	-	-
Tumor size > 10 cm	1.07	0.64-1.78	0.81	-	-	-
Multiple tumor nodules	1.59	0.91-2.76	0.10	-	-	-
Vp4	1.18	0.68-2.05	0.56	-	-	-
Hepatic vein invasion	3.33	1.40-7.94	0.01	2.01	0.76-5.34	0.16
Bile duct invasion	1.16	0.50-2.71	0.73	-	-	-
Distant metastasis	1.24	0.73-2.09	0.43	-	-	-
Previous locoregional therapy	0.87	0.52-1.45	0.59	-	-	-

HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; RT, radiation therapy; HBsAg, hepatitis B surface antibody; HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; INR, international normalized ratio; AFP, alpha-fetoprotein.